{"url_path":"/sec/tcrt/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered Sale of Equity Securities and Use of Proceeds","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1107421/0001193125-26-227272-index.html","accession_number":"0001193125-26-227272","cik":"0001107421","ticker":"TCRT","issuer_name":"Alaunos Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1107421/0001193125-26-227272-index.html","primary_entity_key":"0001107421","primary_entity_name":"Alaunos Therapeutics, Inc."},"word_count":105,"has_tables":true,"body_markdown":"Item 2. Unregistered Sale of Equity Securities and Use of Proceeds\n\n \n\nThe information set forth below relates to our issuances of securities without registration under the Securities Act of 1933 in reliance on Section 4(a)(2) of the Securities Act, and/or Regulation D promulgated thereunder.\n\n \n\nOn January 12, 2026, members of the Board of Directors of the Company elected to receive compensation in equity rather than in cash for their fourth quarter 2025 board service fees. The total deferred board service fees amounted to $48. In exchange for these deferred fees, the Company issued 16,867 shares of common stock, each with a par value of $0.001."}